Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$14,047 Mln
P/E Ratio
--
P/B Ratio
12.23
Industry P/E
--
Debt to Equity
0.01
ROE
-0.09 %
ROCE
-8.42 %
Div. Yield
0 %
Book Value
11.14
EPS
-0.72
CFO
$-1,426.99 Mln
EBITDA
$-1,603.63 Mln
Net Profit
$-1,559.60 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Intracellular Th (ITCI)
| 57.89 | 2.86 | 57.89 | 93.16 | 28.14 | 55.59 | 18.50 |
|
BSE Sensex*
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Midcap 400#
| -11.96 | -6.24 | -14.95 | -3.87 | 1.45 | 12.76 | 5.99 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Intracellular Th (ITCI)
| 16.47 | 35.34 | 1.11 | 64.59 | -7.32 | 201.23 | -21.24 |
|
S&P Midcap 400
| 12.12 | 14.45 | -14.48 | 23.21 | 11.81 | 24.05 | -12.43 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 234.56 | 29,832.92 | -- | 362.29 | |
| 72.62 | 12,921.95 | -- | 3926.49 | |
| 143.91 | 25,373.49 | 19.24 | 22.55 | |
| 24.61 | 17,003.52 | -- | -94.9 |
Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company that develops and commercializes therapeutics and small molecule drugs for central nervous system (CNS), neuropsychiatric, and neurological disorders. The company offers CAPLYTA... for the treatment of schizophrenia and bipolar depression in adults. It distributes its products through third-party wholesale drug distributors. The company was founded in 2002 and is based in Bedminster, New Jersey. As of April 2, 2025, Intra-Cellular Therapies, Inc. operates as a subsidiary of Johnson & Johnson Innovative Medicine. Address: 135 Route 202/206, Bedminster, NJ, United States, 07921 Read more
Co-Founder, Chairman & CEO
Dr. Sharon Mates Ph.D.
Co-Founder, Chairman & CEO
Dr. Sharon Mates Ph.D.
Headquarters
Bedminster, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Intracellular Th (ITCI) stood at $ 1,367 Mln as on 31-Dec-24
The share price of Intracellular Th (ITCI) is $131.87 (NASDAQ) as of 02-Apr-2025 09:30 EDT. Intracellular Th (ITCI) has given a return of 28.14% in the last 3 years.
Intracellular Th (ITCI) has a market capitalisation of $ 14,047 Mln as on 02-Apr-2025. As per Value Research classification, it is a Mid Cap company.
Since, TTM earnings of Intracellular Th (ITCI) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Intracellular Th (ITCI) and enter the required number of quantities and click on buy to purchase the shares of Intracellular Th (ITCI).
Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company that develops and commercializes therapeutics and small molecule drugs for central nervous system (CNS), neuropsychiatric, and neurological disorders. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It distributes its products through third-party wholesale drug distributors. The company was founded in 2002 and is based in Bedminster, New Jersey. As of April 2, 2025, Intra-Cellular Therapies, Inc. operates as a subsidiary of Johnson & Johnson Innovative Medicine. Address: 135 Route 202/206, Bedminster, NJ, United States, 07921
The CEO & director of Dr. Sharon Mates Ph.D.. is Intracellular Th (ITCI), and CFO & Sr. VP is Dr. Sharon Mates Ph.D..
There is no promoter pledging in Intracellular Th (ITCI).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
2,983
|
|
|
2,617
|
|
|
1,700
|
|
|
1,292
|
| Intracellular Th (ITCI) | Ratios |
|---|---|
|
Return on equity(%)
|
-8.58
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
-10.97
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Intracellular Th (ITCI) was $0 Mln.
